We’re looking forward to the 10th #DermatologyDrugDevelopmentSummit this week in Boston. Our CMO, José Trevejo, M.D., Ph.D., will share insights on the importance of standardizing global clinical trial conduct. More details below!

Today we reported third quarter 2026 financial results and provided a corporate update. Learn more: bit.ly/3WmD2ck $QTTB

Today we announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA trial of bempikibart in #alopeciaareata presented in a late-breaking oral and poster presentation at #EADV2026. Learn more: bit.ly/4xQ0rzJ

We were honored to join the alopecia areata community in Boston at the @NAAF_org’s Walk for Alopecia Celebration – despite the rain, we were able to convert our walk into an indoor dance party!

Thank you to everyone who came out in support of people living with #alopeciaareata.

Additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA trial of bempikibart in #alopeciaareata will be featured in late-breaking oral and poster presentations at #EADV2026 on Sep. 30.
Learn more: bit.ly/4AmMcF4

Excited to welcome José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer as we prepare to advance bempikibart into a registration-directed program for #alopeciaareata. Learn more: bit.ly/4rcLJkS

It’s #AlopeciaAreata (AA) Awareness Month, a time to shed light on this disease and its impact on patients. We are advancing our lead candidate, bempikibart, a targeted biologic therapy for patients with AA.

We look forward to participating in the @WellsFargo 21st Annual Healthcare Conference on Sept 8, the Cantor Global Healthcare Conference 2026 on Sept 9, and the @MorganStanley 24th Annual Global Healthcare Conference on Sept 15. More details: bit.ly/4gGpkHP

Today we reported second quarter 2026 financial results and provided a corporate update. Learn more: bit.ly/4wJXTUe
$QTTB

We are thrilled to announce positive 36-week topline results from Part B of our SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe #alopeciaareata.

Read the full press release: bit.ly/4vCbV9e

We’re pleased to support and attend the Annual @NAAF_org Conference this week in Orlando as we continue our work to advance potential treatment options for #alopeciaareata.

#NAAF41Conf #NAAF

Clinical trials are essential to our work to advance potential new treatment options for #alopeciaareata. On #ClinicalTrialsDay, we extend our gratitude to our clinical trials team and to all who support or participate in clinical research. #CTD2026

Today we reported first quarter 2026 financial results and provided a corporate update. Learn more: bit.ly/4wbNy3k $QTTB

We look forward to participating in the 25th Annual Needham Virtual Healthcare Conference next week. Tune in to our fireside chat on Wednesday, April 15th at 12:45 p.m. ET. Find webcast details here: bit.ly/4cv6gLv

Our CEO, Jodie Morrison, spoke with @BiotechTV about the ongoing Part B portion of our SIGNAL-AA clinical trial evaluating bempikibart in severe or very severe #alopeciaareata. Thanks to @bradloncar!
Learn more about bempikibart and our ongoing trial: bit.ly/4sx4dMJ

Today we reported fourth quarter 2025 financial results and provided a corporate update. Learn more: bit.ly/40rlvyq $QTTB

We look forward to participating in the @Oppenheimer 36th Annual Healthcare Life Sciences Conference next week. Tune in to our fireside chat on Wednesday, February 25th at 2:00 p.m. ET. More details here: bit.ly/4cG2SxQ

Maria Marzilli has been appointed Chief Business Officer of Q32 Bio! Having been with the Company since 2019, Maria will continue to be instrumental in guiding BD as we work to advance therapies for #alopeciaareata and other #autoimmunediseases.

Today we reported third quarter 2025 financial results and provided a corporate update. Learn more: bit.ly/4qWo6MR $QTTB

We are excited to announce that we have completed enrollment and exceeded our enrollment target in Part B of our SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe #alopeciaareata (AA).

Learn more: bit.ly/42SJoRb